Leronlimab Shows Inhibits Colon Carcinoma Metastases to Liver & Lung in Preclinical Studies: Can the Sponsor Finance Clinicals?

CytoDyn’s PRO 140, a CCR5 antagonist called leronlimab, inhibited a human colon carcinoma cell line, SW480, metastases to liver and lung in a well-accepted mouse model in pre-clinical research phase. Cytodyn, a small emerging biotech, was recently cleared by the FDA...

2018 Global BioPharma IP Law Round Up

TrialSite News completes the year with excitement. Founded as a simple and straightforward site to contribute to the cause of transparency in clinical research with a focus on the research site/center, the news site turns six months old on New Year's Day. The founders...

Pin It on Pinterest